BPC-157 for Acute Hamstring Strain Repair — VialBase Research

Trial Summary

This is a landmark Phase 2 trial as one of the first formal clinical studies of BPC-157 (Body Protection Compound-157) in humans. BPC-157 is a pentadecapeptide derived from human gastric juice that has shown remarkable tissue-healing properties across dozens of preclinical studies but has lacked rigorous clinical data until recently.

Design

• Type: Randomized, controlled (likely double-blind, placebo-controlled)
• Population: Athletes or active adults with acute grade 1-2 hamstring strains
• Arms: BPC-157 injection vs. placebo/standard care
• Duration: 8-12 weeks follow-up
• Key measures: Time to return to sport/activity, MRI structural healing assessment, pain scores, functional strength testing

Key Outcomes

Trial is recruiting; no results available yet.

Significance for Peptide Research

This trial is enormous for the peptide community. BPC-157 has been widely used in underground/biohacker settings for injury recovery based on animal data, but this represents the first serious clinical validation attempt. The preclinical evidence shows BPC-157 promotes angiogenesis, tendon/ligament/muscle healing, and anti-inflammatory effects via multiple pathways (NO system, growth factors, FAK-paxillin signaling). Formal clinical data would either validate or refute years of anecdotal use. This is a critical step for BPC-157 clinical validation.

See Also

• Related compound: BPC-157